Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
@JT
What are the disadvantages to the FDA of approval after P1a with confirmatory P2/3
Let clinicians decide, where Dox is/ would be the chosen treatment to use a safer better quality of life substitute if they choose for their particular patient ?
"..not sure where you get your reason for talking about someone's margin call... "
Because, despite some good base research, imo MM is not the solution to volatility in Avacta's SP but part of the problem. So a large ill judged margin position is "part of the ball"
At the end of the day he doesn't do himself, or his followers, any favours!
"As was pointed out at the time by MM amongst others (probably yourself included), the DX acquisition was a terrible use of the companies' resources, "
NOT true MM lauded the purchase at the time - changed his tune end of last year.
Threw all his toys out the pram after losing £50k on a poor margin trade earlier this year.
"My understanding was that avacta have the option to repay in cash."
Yes i believe that is correct. My understanding is that Heights have the right to convert any amount at anytime - subject to Avacta repaying in cash if they have it.
Do Avacta have a spare £38m ?
Wasn't the patent reference to Sucrase rather than Sucrose ?
I'm no expert - could this be rellevant ?
Purpose: Expression of disaccharidase sucrase-isomaltase (SI) is significantly enhanced during neoplastic transformation of colonic epithelium. Our study was designed to determine whether expression of SI within primary tumors was significantly associated with survival in patients with colorectal carcinoma (CRC).